Vitrolife Q1: The outcome confirms a more normal business activity - Redeye

Vitrolife’s previous Q1 confirms more normal activity with improved organic growth to 11% from the last Q4 dip to 4%. A recovery of IVF cycles and improved support from Asia contributes to the enhanced trading. This period of some pressure on EBIT and gross margins is likely to contribute to some near-term nervousness.

Länk till analysen i sin helhet: https://www.redeye.se/research/838966/vitrolife-q1-the-outcome-confirms-a-more-normal-business-activity?utm_source=finwire&utm_medium=RSS